Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation

• Asıl Yazarlar: Tamás László (Yazar), Lili Kotmayer (Yazar), Viktória Fésüs (Yazar), Lajos Hegyi (Yazar), Stefánia Gróf (Yazar), Ákos Nagy (Yazar), Béla Kajtár (Yazar), Alexandra Balogh (Yazar), Júlia Weisinger (Yazar), Tamás Masszi (Yazar), Zsolt Nagy (Yazar), Péter Farkas (Yazar), Judit Demeter (Yazar), Ildikó Istenes (Yazar), Róbert Szász (Yazar), Lajos Gergely (Yazar), Adrienn Sulák (Yazar), Zita Borbényi (Yazar), Dóra Lévai (Yazar), Tamás Schneider (Yazar), Piroska Pettendi (Yazar), Emese Bodai (Yazar), László Szerafin (Yazar), László Rejtő (Yazar), Árpád Bátai (Yazar), Mária Á Dömötör (Yazar), Hermina Sánta (Yazar), Márk Plander (Yazar), Tamás Szendrei (Yazar), Aryan Hamed (Yazar), Zsolt Lázár (Yazar), Zsolt Pauker (Yazar), Gáspár Radványi (Yazar), Adrienn Kiss (Yazar), Gábor Körösmezey (Yazar), János Jakucs (Yazar), Péter J Dombi (Yazar), Zsófia Simon (Yazar), Zsolt Klucsik (Yazar), Mihály Gurzó (Yazar), Márta Tiboly (Yazar), Tímea Vidra (Yazar), Péter Ilonczai (Yazar), András Bors (Yazar), Hajnalka Andrikovics (Yazar), Miklós Egyed (Yazar), Tamás Székely (Yazar), András Masszi (Yazar), Donát Alpár (Yazar), András Matolcsy (Yazar), Csaba Bödör (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2024-01-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract TP53 aberrations predict chemoresistance and represent a contraindication for the use of standard chemoimmunotherapy in chronic lymphocytic leukaemia (CLL). Recent next‐generation sequencing (NGS)‐based studies have identified frequent low‐burden TP53 mutations with variant allele frequenci...